MA51200A - Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies - Google Patents
Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladiesInfo
- Publication number
- MA51200A MA51200A MA051200A MA51200A MA51200A MA 51200 A MA51200 A MA 51200A MA 051200 A MA051200 A MA 051200A MA 51200 A MA51200 A MA 51200A MA 51200 A MA51200 A MA 51200A
- Authority
- MA
- Morocco
- Prior art keywords
- diseases
- treatment
- pharmaceutical compositions
- new compounds
- associated pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720101.3A GB201720101D0 (en) | 2017-12-02 | 2017-12-02 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| GBGB1817343.5A GB201817343D0 (en) | 2018-10-25 | 2018-10-25 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51200A true MA51200A (fr) | 2020-10-07 |
Family
ID=64564856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051200A MA51200A (fr) | 2017-12-02 | 2018-11-26 | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11339166B2 (fr) |
| EP (1) | EP3717471B1 (fr) |
| JP (1) | JP7326276B2 (fr) |
| KR (1) | KR102720958B1 (fr) |
| CN (1) | CN111433200B (fr) |
| AU (1) | AU2018374456B2 (fr) |
| BR (1) | BR112020010364A2 (fr) |
| CA (1) | CA3084090A1 (fr) |
| CO (1) | CO2020008066A2 (fr) |
| CY (1) | CY1125044T1 (fr) |
| DK (1) | DK3717471T3 (fr) |
| ES (1) | ES2908283T3 (fr) |
| HU (1) | HUE057581T2 (fr) |
| IL (1) | IL274938B2 (fr) |
| MA (1) | MA51200A (fr) |
| MX (1) | MX2020005423A (fr) |
| MY (1) | MY201849A (fr) |
| PH (1) | PH12020550725B1 (fr) |
| PL (1) | PL3717471T3 (fr) |
| PT (1) | PT3717471T (fr) |
| SG (1) | SG11202004925QA (fr) |
| TW (1) | TW201930301A (fr) |
| WO (1) | WO2019105886A1 (fr) |
| ZA (1) | ZA202004025B (fr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2876689C (fr) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Composes tricycliques substitues utilises comme inhibiteurs de fgfr |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CA2976790C (fr) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr |
| WO2018053373A1 (fr) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Utilisations d'inhibiteurs de kinase inductible par un sel (sik) pour traiter l'ostéoporose |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019105886A1 (fr) * | 2017-12-02 | 2019-06-06 | Galapagos Nv | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| WO2020185532A1 (fr) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr |
| GB201907558D0 (en) | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| GB201907616D0 (en) * | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositons thereof for the treatment of diseases |
| WO2021007269A1 (fr) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021113479A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| US12012409B2 (en) * | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3174353A1 (fr) * | 2020-04-08 | 2021-10-14 | Dominic Reynolds | Composes et procedes de modulation de l'epissage |
| AU2021320860A1 (en) * | 2020-08-05 | 2023-02-23 | The General Hospital Corporation | Salt inducible kinase inhibitors |
| CN112010860B (zh) * | 2020-08-05 | 2023-03-10 | 南京纳丁菲医药科技有限公司 | 苄氧基吡唑并嘧啶化合物和药物组合物及其应用 |
| MX2023003677A (es) * | 2020-09-30 | 2023-06-22 | Fl2022 001 Inc | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. |
| JP7805363B2 (ja) | 2020-11-02 | 2026-01-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体 |
| US20240174662A1 (en) * | 2021-02-01 | 2024-05-30 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| EP4284801A4 (fr) * | 2021-02-01 | 2025-04-23 | Janssen Biotech, Inc. | Inhibiteurs à petites molécules de kinases inductibles par le sel |
| EP4323405A1 (fr) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4 |
| CN113336751A (zh) * | 2021-05-31 | 2021-09-03 | 南京谷睿生物科技有限公司 | 一种高效盐诱导激酶抑制剂及其制备方法 |
| CA3220274A1 (fr) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Heterocycles tricycliques en tant qu'inhibiteurs de fgfr |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| KR20230053049A (ko) * | 2021-10-13 | 2023-04-21 | 서울대학교산학협력단 | 류마티스 관절염 예방 또는 치료용 약학적 조성물 및 건강기능식품 |
| CN118119619A (zh) * | 2021-10-18 | 2024-05-31 | 上海美悦生物科技发展有限公司 | Sik抑制剂及其组合物、制备方法和用途 |
| AR128279A1 (es) * | 2022-01-19 | 2024-04-10 | Hoffmann La Roche | Nuevos derivados de bencimidazol piridina |
| AR128280A1 (es) * | 2022-01-19 | 2024-04-10 | Hoffmann La Roche | Derivados de bencimidazol piridina |
| US20250171438A1 (en) * | 2022-02-28 | 2025-05-29 | Agios Pharmaceuticals, Inc. | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations |
| KR20240154642A (ko) * | 2022-02-28 | 2024-10-25 | 아지오스 파마슈티컬스 아이엔씨. | 페닐알라닌 하이드록실라아제 돌연변이의 안정화에 유용한 화합물 및 방법 |
| CN117843634A (zh) * | 2022-05-24 | 2024-04-09 | 上海美悦生物科技发展有限公司 | Sik抑制剂及其组合物、制备方法和用途 |
| WO2024003208A1 (fr) * | 2022-07-01 | 2024-01-04 | F. Hoffmann-La Roche Ag | Dérivés d'imidazo[4,5-b]pyridine et de pyrazolo[1,5-a]pyrimidine utilisés en tant que modulateurs de sik pour le traitement de la polyarthrite rhumatoïde |
| US20240124450A1 (en) * | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
| EP4642773A1 (fr) * | 2022-12-27 | 2025-11-05 | F. Hoffmann-La Roche AG | Nouveaux dérivés de benzimidazole |
| EP4737443A1 (fr) | 2023-05-24 | 2026-05-06 | Tanabe Pharma Corporation | Composé inhibiteur de kinase inductible par un sel et composition pharmaceutique le contenant |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
| AR133277A1 (es) | 2023-07-19 | 2025-09-10 | Hoffmann La Roche | Nuevos derivados de bencimidazol piridina |
| WO2025017041A1 (fr) * | 2023-07-19 | 2025-01-23 | F. Hoffmann-La Roche Ag | Benzimidazoles utilisés en tant que modulateurs de l'activité sik |
| WO2025231112A1 (fr) * | 2024-05-01 | 2025-11-06 | Nimbus Salacia, Inc. | Modulateurs de sik2 et leurs utilisations |
| WO2025231117A1 (fr) * | 2024-05-01 | 2025-11-06 | Nimbus Salacia, Inc. | Modulateurs de sik2 et leurs utilisations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008279759A1 (en) | 2007-07-20 | 2009-01-29 | Merck & Co., Inc. | Pyrazolo[1,5-a]pyrimidine derivatives |
| KR101150581B1 (ko) | 2007-07-26 | 2012-06-11 | 노파르티스 아게 | 유기 화합물 |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| CA2732520A1 (fr) * | 2008-08-05 | 2010-02-11 | Merck Sharp & Dohme Corp. | Composes therapeutiques |
| GB201204384D0 (en) * | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
| US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| AU2016315881B2 (en) * | 2015-09-03 | 2019-09-19 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| WO2019105886A1 (fr) * | 2017-12-02 | 2019-06-06 | Galapagos Nv | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies |
| AU2021320860A1 (en) | 2020-08-05 | 2023-02-23 | The General Hospital Corporation | Salt inducible kinase inhibitors |
-
2018
- 2018-11-26 WO PCT/EP2018/082537 patent/WO2019105886A1/fr not_active Ceased
- 2018-11-26 US US16/768,825 patent/US11339166B2/en active Active
- 2018-11-26 HU HUE18811769A patent/HUE057581T2/hu unknown
- 2018-11-26 MA MA051200A patent/MA51200A/fr unknown
- 2018-11-26 MY MYPI2020002758A patent/MY201849A/en unknown
- 2018-11-26 DK DK18811769.1T patent/DK3717471T3/da active
- 2018-11-26 CA CA3084090A patent/CA3084090A1/fr active Pending
- 2018-11-26 PT PT188117691T patent/PT3717471T/pt unknown
- 2018-11-26 KR KR1020207019014A patent/KR102720958B1/ko active Active
- 2018-11-26 SG SG11202004925QA patent/SG11202004925QA/en unknown
- 2018-11-26 JP JP2020529717A patent/JP7326276B2/ja active Active
- 2018-11-26 IL IL274938A patent/IL274938B2/en unknown
- 2018-11-26 ES ES18811769T patent/ES2908283T3/es active Active
- 2018-11-26 MX MX2020005423A patent/MX2020005423A/es unknown
- 2018-11-26 PL PL18811769T patent/PL3717471T3/pl unknown
- 2018-11-26 CN CN201880077841.9A patent/CN111433200B/zh active Active
- 2018-11-26 AU AU2018374456A patent/AU2018374456B2/en active Active
- 2018-11-26 PH PH1/2020/550725A patent/PH12020550725B1/en unknown
- 2018-11-26 EP EP18811769.1A patent/EP3717471B1/fr active Active
- 2018-11-26 BR BR112020010364-0A patent/BR112020010364A2/pt active IP Right Grant
- 2018-11-30 TW TW107142872A patent/TW201930301A/zh unknown
-
2020
- 2020-06-30 CO CONC2020/0008066A patent/CO2020008066A2/es unknown
- 2020-07-01 ZA ZA2020/04025A patent/ZA202004025B/en unknown
-
2022
- 2022-03-02 CY CY20221100182T patent/CY1125044T1/el unknown
- 2022-04-13 US US17/719,653 patent/US12065443B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires | |
| EP3716767A4 (fr) | Méthodes et compositions pour le traitement de maladies rares | |
| MA51739A (fr) | Compositions pharmaceutiques pour le traitement de la fibrose kystique | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448987A4 (fr) | Compositions pour le traitement de maladies | |
| MA52118A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| EP3431105A4 (fr) | Composition médicinale pour le traitement du cancer | |
| EP3390634A4 (fr) | Compositions et méthodes pour le traitement de maladies oculaires | |
| EP3621973A4 (fr) | Composés pour la prévention et le traitement de maladies et leur utilisation | |
| EP3866781A4 (fr) | Nouvelles compositions pour le traitement de maladies inflammatoires | |
| EP3448398A4 (fr) | Compositions et méthodes pour le traitement de troubles cutanés | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| EP3661553A4 (fr) | Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes | |
| PL3717471T3 (pl) | Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób | |
| EP4045037C0 (fr) | Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1 | |
| EP3649157A4 (fr) | Compositions et méthodes de traitement ou de prévention de maladies liées au fgf endocrinien | |
| EP3328864A4 (fr) | Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie | |
| EP3846830A4 (fr) | Méthodes et compositions pour le traitement de maladie musculo-squelettiques | |
| EP3621593A4 (fr) | Compositions pharmaceutiques et méthodes de traitement de maladies cardiovasculaires | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| EP3352749A4 (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| EP3655403A4 (fr) | Composés affectant la production de pigments et leur utilisation pour le traitement de maladies bactériennes | |
| EP3481958A4 (fr) | Procédés et compositions de traitement de troubles et de maladies impliquant rdh12 |